

```

chain nodes :
  13 15 16 17
ring nodes :
  1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 23
ring/chain nodes :
  11
chain bonds :
  13-15 15-16 15-17 17-23
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21 21-22
  22-23
exact/norm bonds :
  13-15 15-16 15-17 17-23
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21 21-22
  22-23
isolated ring systems :
  containing 1 : 18 :

```

```

Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
  12:Atom 13:CLASS 14:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
  22:Atom 23:Atom
Generic attributes :
  17:
  Saturation : Unsaturated
  Number of Carbon Atoms : less than 7
  Number of Hetero Atoms : 2 or more
  Type of Ring System : Monocyclic

```

```


Element Count :
  Node 17: Limited
  C,C4
  N,N2

```

0,00
S,S0

=>

Uploading C:\Program Files\Stnexp\Queries\10556932.str



chain nodes :

13 15 16 17

ring nodes :

1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 23

ring/chain nodes :

11

chain bonds :

13-15 15-16 15-17 17-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21
21-22 22-23

exact/norm bonds :

13-15 15-16 15-17 17-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 18-19 18-23 19-20 20-21
21-22 22-23

isolated ring systems :

containing 1 : 18 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:CLASS 14:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

C,C4

N,N2

O,O0

S,S0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:05:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15663 TO ITERATE

12.8% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 305764 TO 320756

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 14:06:01 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 314424 TO ITERATE

100.0% PROCESSED 314424 ITERATIONS 15 ANSWERS
SEARCH TIME: 00.00.03

L3 15 SEA SSS FUL L1

=> => s l3

L4 1 L3

=> d l4 bib,ab,hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:1037093 CAPLUS
 DN 142:23303
 TI Preparation of pyrimidine derivatives having 2-aminoquinoline moiety as
 MCH receptor antagonists
 IN Moriya, Minoru; Suzuki, Takao; Ishihara, Akane; Iwaasa, Hisashi; Kanatani,
 Akio
 PA Banyu Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103992	A1	20041202	WO 2004-JP7217	20040520
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004241213	A1	20041202	AU 2004-241213	20040520
CA 2526374	A1	20041202	CA 2004-2526374	20040520
EP 1630162	A1	20060301	EP 2004-734111	20040520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1791594	A	20060621	CN 2004-80013778	20040520
IN 2005DN04938	A	20071207	IN 2005-DN4938	20051027
US 20060287340	A1	20061221	US 2005-556932	20051116
PRAI JP 2003-143398	A	20030521		
WO 2004-JP7217	W	20040520		

OS MARPAT 142:23303

AB Title compds. I [R1, R2 = alkyl, etc.; R3, R4, R6, R7 = H, alkyl, etc.; R5 = H, alkyl; R8 = halo, etc.; n = 0-4] were prepared For example, hydrogenation of nitro compound (R)-II followed by acylation with 5-phenylpyrimidine-2-carboxylic acid afforded compound (R)-III. In MCH (melanin concentrating hormone) binding assays, the IC50 value of compound (R)-III was 4.1 nM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc.


IT 801252-02-8P 801252-05-1P 801252-08-4P
 801252-11-9P 801252-14-2P 801252-17-5P
 801252-21-1P 801252-26-6P 801252-31-3P
 801252-34-6P 801252-37-9P 801252-40-4P
 801252-43-7P 801252-46-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. having 2-aminoquinoline moiety as MCH receptor antagonists for treatment of obesity, diabetes, etc.)


RN 801252-02-8 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4.4]non-7-yl)-6-quinolinyl]- (CA INDEX NAME)



RN 801252-05-1 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-(2-methyl-3-oxo-2,7-diazaspiro[4.4]non-7-yl)-6-quinolinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 801252-08-4 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[methyl(2-methyl-1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-11-9 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-(6-acetyloctahydropyrrolo[3,4-d]azepin-2(1H)-yl)-6-quinolinyl]-5-phenyl- (CA INDEX NAME)



RN 801252-14-2 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-(acetylmethylamino)-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 801252-17-5 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[methyl(1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 801252-21-1 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[methyl(methylsulfonyl)amino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 801252-26-6 CAPLUS

CN Carbamic acid, methyl[(3R)-1-[6-[(5-phenyl-2-pyrimidinyl)carbonyl]amino]-2-quinolinyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 801252-31-3 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-[(dimethylamino)carbonyl]methylamino]-1-pyrrolidinyl]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 801252-34-6 CAPLUS


CN 2-Pyrimidinecarboxamide, N-[2-[methyl(1-methylethyl)amino]-6-quinolinyl]-5-phenyl- (CA INDEX NAME)



RN 801252-37-9 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-[(3R)-3-[methyl(2-methyl-1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 801252-40-4 CAPLUS

CN 2-Pyrimidinecarboxamide, N-[2-[(3R)-3-(acetylmethylamino)-1-pyrrolidinyl]-6-quinolinyl]-5-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 801252-43-7 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-(4-fluorophenyl)-N-[2-[methyl(tetrahydro-3-furanyl)amino]-6-quinolinyl]- (CA INDEX NAME)


10/556,932



RN 801252-46-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 5-(3-fluorophenyl)-N-[2-[(3R)-3-[methyl(2-methyl-1-oxopropyl)amino]-1-pyrrolidinyl]-6-quinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/556,932

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.93

184.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.80

-0.80

STN INTERNATIONAL LOGOFF AT 14:06:36 ON 22 JUN 2008